Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome
Authors:
Open Access
- 14 August 2012
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (1) , 69-75
Abstract
In a placebo-controlled study, denileukin diftitox (DD) was effective against cutaneous T-cell lymphoma (CTCL) expressing CD25. An open-label companion study examined the efficacy and safety of DD in 36 patients with skin biopsies containing < 20% CD25 cells by immunohistochemistry staining (CD25 low expression). Patients received DD 18 μg/kg/day for 5 consecutive days every 3 weeks for up to eight courses. The primary endpoint, overall response rate, was 30.6% (95% confidence interval: 16.3, 48.1), 33.3% for stage IIA or lower disease, and 26.7% for stage IIB or greater disease. Median progression-free survival (PFS) was > 487 days, and median time to treatment failure was 68.5 days. No difference in PFS by disease stage was observed. The safety profile of DD in CD25 low-expression disease was similar to that in CD25+ disease. These findings suggest that CD25 low expression does not preclude a meaningful clinical response to DD in patients with CTCL.Keywords
This publication has 17 references indexed in Scilit:
- Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placeboJournal of the American Academy of Dermatology, 2012
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Degree of CD25 Expression in T-Cell Lymphoma Is Dependent on Tissue SiteClinical Cancer Research, 2004
- Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic ApproachesLeukemia & Lymphoma, 2003
- Treatment of Refractory Peripheral T-cell Lymphoma with Denileukin Diftitox (ONTAK ® )Leukemia & Lymphoma, 2002
- A modified staging classification for cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2001
- Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2001
- Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignanciesEuropean Journal of Cancer, 1997
- Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells.1996
- Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.1979